# Bunion Treatment Market

> 拇外翻（大脚趾外翻）治疗市场研究报告信息，按诊断（病史、X光、放射摄影）、按治疗（自我护理、药物、设备、手术）、按最终用户（医疗服务提供者和足病医生）以及按地区（北美、欧洲、亚太和世界其他地区）–市场预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.8%
- **2024:** $ 23.5 Million
- **2025:** $ 25.09 Million
- **2035:** $ 48.46 Million
- **Key Players:** Companies such as B. Braun Melsungen AG (DE), Stryker Corporation (US), Zimmer Biomet Holdings, Inc. (US), DePuy Synthes (US), Smith & Nephew plc (GB), Acelity L.P. Inc. (US), Medtronic plc (IE), Orthofix Medical Inc.(US), Hanger, Inc. (US) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/3757-HCR · **Pages:** 90 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/bunion-treatment-market-5195

---

## Market Summary

Global Bunion Treatment Market Size was valued at USD 23.50 Million in 2024 & the market is projected to grow from USD 25.09 Million in 2025 to USD 48.46 Million by 2035, registering a CAGR of 6.80% during the forecast period 2025–2035. North America led the market with over 44.68% share, generating around USD 10.5 Million in revenue.
 
The rising prevalence of hallux valgus, particularly among older adults, is increasing demand for surgical and conservative treatments. Greater diagnosis, aging populations, and improved access to orthopedic care are expanding the addressable patient pool and supporting continued growth in bunion treatment services.
 
A PubMed meta-analysis covering 45 studies and 186.3 million people estimated global hallux valgus prevalence at 19%, rising to 22.7% among adults over 60, highlighting substantial treatment potential.

## Market Drivers

### Rising Awareness and Education

对拇囊炎及其治疗方案的认识的提高是全球拇囊炎（拇外翻）治疗市场行业的关键驱动力。医疗保健提供者和协会开展的教育活动使公众更加了解这种情况及其影响。
 
患者现在更加了解可用的治疗方法，包括保守治疗和手术治疗。这种意识的提高可能会导致更多的人寻求医疗建议和治疗，从而扩大市场。随着意识的不断增强，预计对拇囊炎治疗的需求将进一步增加，从而有助于市场扩张。

- 一项涵盖 45 项研究和 1.863 亿人的 PubMed 系统回顾和荟萃分析估计，全球拇外翻患病率为 19%，为该疾病的大量患者基础以及认识、诊断和获得治疗的重要性提供了强有力的证据。

### Advancements in Surgical Techniques

拇囊炎矫正外科手术的创新正在显着影响全球拇囊炎（拇外翻）治疗市场行业。微创技术，例如关节镜检查，改善了患者的治疗效果并缩短了康复时间。
 
 这些进步不仅提高了治疗的有效性，而且还吸引了寻求更快康复的患者。因此，市场预计将从 2024 年的 0.02 亿美元增长到 2035 年的 0.05 亿美元，反映出 2025 年至 2035 年复合年增长率 (CAGR) 为 9.34%。这一趋势表明转向更高效、对患者友好的治疗方案。

- PubMed 证据证明了现代外科管理的持续临床价值。在一项对 209 名患者进行的随机试验中，83% 接受手术的患者报告一年后病情有所改善，而接受矫形器治疗的患者为 46%，对照组为 24%。

### Growing Adoption of Orthotic Devices

全球拇囊炎（拇外翻）治疗市场行业也受到越来越多采用的推动[矫形器](https://www.marketresearchfuture.com/reports/orthotic-devices-market-2858)。这些设备包括定制鞋垫和拇囊炎夹板，提供非侵入性治疗选择，可减轻疼痛并改善足部功能。
 
预防性护理和足部健康自我管理的趋势不断增长，导致这些产品的使用量增加。随着消费者健康意识的增强，对矫形解决方案的需求预计将会增长。随着越来越多的人寻求有效的非手术替代方案来治疗拇囊炎，这种趋势可能会促进整体市场的增长。

- PubMed 对 53 名拇外翻患者进行的为期两年的随访研究发现，足部矫形器治疗的疼痛减轻效果可持续 24 个月，而 81% 的参与者在随访结束时继续使用矫形器。

### Increasing Prevalence of Bunion Cases

由于拇囊炎在不同人群中的患病率不断上升，全球拇囊炎（拇外翻）治疗市场行业正在经历增长。人口老龄化和生活方式选择等因素导致了这一增长。
 
例如，拇囊炎在老年人中更为常见，研究表明，大约 23% 的 18-65 岁人群和 36% 的 65 岁以上人群受到影响。这种不断增长的发病率需要有效的治疗方案，从而扩大市场。随着人口持续老龄化，拇囊炎治疗的需求预计将上升，进一步推动市场增长。

- 一项大型 PubMed 荟萃分析发现，18-65 岁成年人中拇外翻患病率为 23%，65 岁以上人群中拇外翻患病率为 35.7%，这表明老年人群的负担要高得多，并支持对与年龄相关的足部护理和治疗解决方案不断增长的需求。

## Segment Insights

### 按治疗类型：手术治疗（最大）与非手术治疗（增长最快）

在拇囊炎治疗市场中，手术治疗目前占据最大份额，为 55%，这反映出其长期以来被认为是严重拇囊炎病例的有效解决方案。由于患者意识的提高和对侵入性较小的选择的偏好的推动，非手术治疗正在受到越来越多的关注。矫形装置和物理治疗也对整体市场动态做出了贡献，但所占市场份额较小。这一趋势说明了满足不同患者需求的各种治疗方案之间的平衡竞争。拇囊炎治疗领域的增长趋势在很大程度上受到手术技术进步和非手术干预疗效提高的影响。老年人口的增加（更容易出现拇囊炎）支持了对有效治疗方案的需求。此外，矫形技术的发展和获得更多机会 [物理治疗服务](https://www.marketresearchfuture.com/reports/physical-therapy-services-market-67558)有助于促进这些领域的增长。市场正在向个性化治疗计划转变，进一步推动了这些趋势。

B. Braun Melsungen AG 强调敏捷、以用户为中心的医疗技术研发，特别强调微创手术方面的专业知识，支持围绕手术治疗解决方案的持续创新。

### 按严重程度划分：中等（最大）与严重（增长最快）

在拇囊炎治疗市场中，不同严重程度的市场份额分布表明，中度拇囊炎占据最大份额，达 48%，因其大量寻求治疗的患者群体而引起关注。紧随其后的是重症部分，虽然目前所占比例较小，但由于对更危重病例的认识不断提高和治疗方案的进步，该部分正在取得进展。尽管存在轻度部分，但与更严重的部分相比，其所占份额较小，这表明正在转向解决更明显的情况。随着市场的发展，增长趋势表明，严重的细分市场增长最快，主要是由于人口老龄化、生活方式的改变以及对拇囊炎治疗认识的提高。随着手术技术的进步以及对解决与严重拇囊炎相关的疼痛和活动问题的更加重视，医疗保健提供者越来越关注这一领域。因此，重症病例的增长反映了医疗保健领域更广泛的趋势，强调了随着患者需求的变化解决更复杂的情况的重要性。

Stryker Corporation 通过 Artelon 扩展足踝产品组合，增加了先进的软组织固定技术； Artelon 已在全球范围内完成了 60,000 多次植入，增强了骨科手术的治疗能力。

### 按患者人口统计：成人（最大）与老年人（增长最快）

在拇囊炎治疗市场中，患者人口统计数据显示，成年人构成了最大的细分市场，由于其普遍的生活方式因素和导致拇囊炎的足部状况，占了 64% 的份额。年轻的成年人口倾向于寻求积极主动的治疗解决方案，从而建立了强大的市场基础，而老年人虽然最初是一个较小的群体，但由于他们不断增长的医疗保健需求和对治疗选择的认识而日益受到认可。这种人口结构的变化表明市场动态发生了根本性变化，不同年龄段的人对治疗解决方案的参与度更高。增长趋势表明，随着老年人对拇囊炎相关问题的认识和诊断的增加，该群体在市场中的比例正在迅速扩大，从而成为拇囊炎治疗市场中增长最快的部分。此外，可支配收入的增加、医疗保健服务的增加以及针对老年人的针对性营销等因素正在推动该细分市场的增长。针对老年人群的创新治疗解决方案正在出现，这表明对特定医疗保健需求的响应，最终导致市场范围扩大和进一步扩张的潜力。

成人（主导）与老年人（新兴）

成年人仍然是市场份额的主导群体，其特点是积极的生活方式，往往会导致拇囊炎等足部并发症。该年龄组通常包括 20 岁至 60 岁之间的个体，他们更有可能从事可能加剧拇囊炎形成的活动，从而推动对治疗方案的需求。另一方面，老年人正在成为这个市场的关键参与者。随着 65 岁及以上人口的不断增加，该群体正在寻求有效的治疗方法来增强活动能力并管理足部健康。这一群体的增长主要是由于人们对拇囊炎疾病的认识提高以及对改善生活质量的渴望，这鼓励老年人寻求治疗干预。

### 按分销渠道：在线销售（最大）与专科诊所（增长最快）

拇囊炎治疗市场呈现出多元化的分销渠道格局，其中在线销售占据最大份额，占据 42% 的市场份额。该渠道利用了电子商务的增长趋势和消费者对便利性的偏好。在线销售之后，药店和医院持有大量份额，以满足寻求立即获得治疗的患者的需求。专科诊所虽然市场份额较小，但在整体分销策略中越来越突出，反映出向有针对性的护理的转变。

药房（主导）与医院（新兴）

药店是市场份额和分销渠道的主导力量，可以轻松获得非处方治疗和支持产品。它们的广泛存在提高了患者的便利性并鼓励持续的参与。相比之下，医院虽然传统上被视为重要的医疗保健提供者，但现在正在成为市场上的重要参与者。他们提供全面的治疗方案，包括手术干预和专业咨询。随着形势的不断变化，医院正在适应提供更多与拇囊炎相关的护理，随着人们对拇囊炎治疗的认识的提高，这些护理也有望实现增长。

## Regional Market Share Analysis

### 北美：拇囊炎治疗的市场领导者

北美在拇囊炎（拇外翻）治疗市场规模方面处于领先地位，到 2024 年将占全球收入的 44.68% 以上。该地区的增长是由足部健康意识的提高、手术技术的进步以及人口老龄化的增加推动的。对创新治疗方案的监管支持进一步刺激了需求，使其成为全球市场的关键参与者。

- CDC 数据显示，2019 年至 2021 年期间，有 5320 万美国成年人（即 21.2%）被诊断出关节炎，其中 2570 万病例发生在 65 岁及以上的成年人中。这种巨大的肌肉骨骼负担增强了对骨科评估、活动管理和相关治疗服务的需求。

美国脱颖而出，成为领先国家，史赛克公司 (Stryker Corporation) 和 Zimmer Biomet Holdings, Inc. 等主要参与者占据主导地位。竞争环境的特点是主要参与者之间的持续创新和战略伙伴关系。随着医疗保健提供者越来越多地采用先进的治疗方式，这个充满活力的市场预计将进一步增长。

- GE HealthCare 通过专为高分辨率评估而设计的 MRI 技术支持先进的肌肉骨骼成像。其 MSK 解决方案包括足部和脚踝解剖学成像功能，而 AIR Recon DL 可以将扫描时间缩短高达 50%，支持高效的骨科诊断和治疗计划。

### 欧洲：具有增长潜力的新兴市场

2024年，欧洲拇囊炎（拇外翻）治疗市场规模达700万美元，成为第二大区域市场，占有29.79%的份额。足部疾病患病率的增加、对治疗选择的认识提高以及支持性医疗政策等因素正在推动这一增长。该地区的监管框架正在不断发展，以适应新技术，增强患者获得有效治疗的机会。

- 欧洲药品管理局推荐114种药品在2024年获得上市许可，其中46种药品含有新活性物质。 EMA 还报告称，获得积极评价的药物中有 60% 在开发过程中受益于科学建议，这反映出欧洲在医疗保健创新和监管进步方面拥有强大的环境。

 德国和英国等领先国家处于领先地位，B. Braun Melsungen AG 和 Smith & Nephew plc 等主要参与者积极参与该市场。竞争格局的特点是公司之间的创新和合作，确保为患者提供多样化的治疗选择。随着市场的成熟，对微创手术的关注预计将获得关注。

### 亚太地区：快速增长的拇囊炎治疗行业

亚太地区正在成为拇囊炎治疗市场的重要参与者，到 2024 年市场规模将达到 4.5。这一增长是由城市化进程加快、可支配收入增加以及足部健康意识不断增强所推动的。此外，旨在改善医疗基础设施的政府支持举措预计将进一步提振市场需求。

 日本和澳大利亚等国家处于领先地位，其竞争格局既有本地企业，也有国际企业。 Medtronic plc 和 Orthofix Medical Inc. 等公司正在扩大其在该地区的业务。对先进手术技术和以患者为中心的解决方案的关注正在塑造亚太地区拇囊炎治疗的未来，使其成为一个值得关注的地区。

### 中东和非洲：潜力尚未开发的新兴市场

中东和非洲地区正在逐步发展拇囊炎治疗市场，目前预计到 2024 年该市场价值为 1.5。这一增长主要是由于医疗保健投资的增加、足部相关疾病患病率的上升以及人们对治疗选择的认识不断提高而推动的。

监管机构开始实施支持引进先进医疗技术的框架，预计这将促进市场增长。南非和阿联酋等国家在市场上处于领先地位，其竞争格局包括本地和国际参与者。 Hanger, Inc. 和 Acelity L.P. Inc. 等主要公司的存在正在为市场的发展做出贡献。随着医疗保健服务的改善，对有效拇囊炎治疗的需求预计将大幅增加。

## Competitive Benchmarking

The Bunion Treatment Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Stryker Corporation (US), Zimmer Biomet Holdings, Inc. (US), and B. Braun Melsungen AG (DE) are actively engaged in enhancing their product offerings and expanding their market reach. Stryker Corporation (US) has positioned itself as a leader through its commitment to technological advancements in surgical solutions, while Zimmer Biomet Holdings, Inc. (US) emphasizes a comprehensive approach to musculoskeletal health, integrating bunion treatments into a broader portfolio of orthopedic solutions.
 
B. Braun Melsungen AG (DE) focuses on developing minimally invasive techniques, which aligns with the growing demand for less invasive treatment options, thereby influencing the competitive dynamics of the market.The business tactics employed by these companies reflect a strategic emphasis on localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share, yet the collective influence of these key players is significant. Their ability to innovate and adapt to changing consumer preferences is likely to dictate the competitive landscape moving forward.
 
In November Stryker Corporation (US) announced the launch of a new line of advanced bunion correction devices that utilize AI-driven technology to enhance surgical precision. This strategic move not only underscores Stryker's commitment to innovation but also positions the company to capture a larger share of the market by addressing the increasing demand for technologically advanced surgical solutions. The integration of AI into surgical procedures may lead to improved patient outcomes and reduced recovery times, thereby enhancing Stryker's competitive edge.
 
In October Zimmer Biomet Holdings, Inc. (US) entered into a strategic partnership with a leading telehealth provider to offer remote consultations for bunion treatment. This collaboration is indicative of a broader trend towards digital health solutions, allowing patients to access expert advice from the comfort of their homes. By leveraging telehealth, Zimmer Biomet aims to improve patient engagement and streamline the treatment process, which could potentially lead to increased patient satisfaction and loyalty.
 
In September B. Braun Melsungen AG (DE) expanded its product line to include biodegradable implants for bunion correction, reflecting a growing trend towards sustainability in medical devices. This strategic initiative not only addresses environmental concerns but also aligns with the increasing consumer preference for eco-friendly products. By prioritizing sustainability, B. Braun may enhance its brand reputation and appeal to a more environmentally conscious consumer base.
 
As of December the competitive trends in the Bunion Treatment Market are increasingly defined by digitalization, sustainability, and the integration of advanced technologies such as AI. Strategic alliances are playing a crucial role in shaping the current landscape, enabling companies to leverage complementary strengths and enhance their market positions. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies approach product development and customer engagement, ultimately leading to improved patient outcomes and satisfaction.

## Recent News & Developments

- Q3 2024: Robert Wood Johnson University Hospital (RWJUH) at New Jersey, U.S started offering the Bunionplasty 360 Bunion Repair, a minimally invasive procedure that uses small incisions and patented bone screws to realign the toe joint. In August 2024, RWJUH in New Jersey launched the Bunionplasty 360 Bunion Repair, a new minimally invasive bunion surgery technique designed to minimize scarring, reduce pain, and accelerate recovery, allowing patients to walk the same day and return to normal footwear within 6–8 weeks.

## Report Scope

| MARKET SIZE 2024 | 23.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 25.09(USD Million) |
| MARKET SIZE 2035 | 48.46(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | B. Braun Melsungen AG (DE), Stryker Corporation (US), Zimmer Biomet Holdings, Inc. (US), DePuy Synthes (US), Smith & Nephew plc (GB), Acelity L.P. Inc. (US), Medtronic plc (IE), Orthofix Medical Inc. (US), Hanger, Inc. (US) |
| Segments Covered | Treatment Type, Severity Level, Patient Demographics, Distribution Channel |
| Key Market Opportunities | Integration of advanced minimally invasive surgical techniques in the Bunion Treatment Market. |
| Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation and competition in the bunion treatment market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Bunion Treatment Market by 2035?**
A: The projected market valuation of the Bunion Treatment Market is expected to reach 48.46 USD Million by 2035.

**Q: What was the market valuation of the Bunion Treatment Market in 2024?**
A: The overall market valuation of the Bunion Treatment Market was 23.5 USD Million in 2024.

**Q: What is the expected CAGR for the Bunion Treatment Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Bunion Treatment Market during the forecast period 2025 - 2035 is 6.8%.

**Q: Which companies are considered key players in the Bunion Treatment Market?**
A: Key players in the Bunion Treatment Market include B. Braun Melsungen AG, Stryker Corporation, and Zimmer Biomet Holdings, Inc.

**Q: What are the main treatment types in the Bunion Treatment Market?**
A: The main treatment types in the Bunion Treatment Market include Surgical Treatment, Non-Surgical Treatment, Orthotic Devices, and Physical Therapy.

**Q: How did the valuation of Surgical Treatment compare to Non-Surgical Treatment in 2024?**
A: In 2024, the valuation of Surgical Treatment was 8.0 USD Million, while Non-Surgical Treatment was valued at 7.5 USD Million.

**Q: What is the market segmentation by severity level for bunion treatment?**
A: The market segmentation by severity level includes Mild, Moderate, and Severe, with valuations ranging from 5.0 to 20.0 USD Million.

**Q: How do patient demographics influence the Bunion Treatment Market?**
A: Patient demographics, including Age Group, Gender, and Activity Level, show valuations from 8.0 to 16.96 USD Million.

**Q: What distribution channels are utilized in the Bunion Treatment Market?**
A: Distribution channels in the Bunion Treatment Market include Online Sales, Pharmacies, Hospitals, and Specialty Clinics.

**Q: What is the projected growth trend for the Bunion Treatment Market in the coming years?**
A: The Bunion Treatment Market is likely to experience growth, with a projected valuation increase to 48.46 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bunion-treatment-market-5195*